Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Lowered to $14.00 at Chardan Capital

Iovance Biotherapeutics (NASDAQ:IOVA) had its target price reduced by Chardan Capital from $16.00 to $14.00 in a research note released on Thursday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other equities analysts have also recently weighed in on the stock. Citizens Jmp upgraded shares of Iovance Biotherapeutics from a “market perform” rating to a “market outperform” rating and set a $5.00 price objective for the company in a research report on Tuesday, March 3rd. Wall Street Zen upgraded shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Barclays boosted their target price on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. The Goldman Sachs Group restated a “sell” rating and set a $2.00 price target on shares of Iovance Biotherapeutics in a research report on Thursday, February 5th. Finally, Truist Financial upgraded Iovance Biotherapeutics to a “hold” rating in a report on Wednesday, March 25th. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $8.63.

Iovance Biotherapeutics Trading Down 0.2%

IOVA traded down $0.01 during trading on Thursday, hitting $3.54. The company’s stock had a trading volume of 4,980,545 shares, compared to its average volume of 15,253,746. The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of -3.16 and a beta of 0.69. Iovance Biotherapeutics has a twelve month low of $1.64 and a twelve month high of $5.63. The business’s fifty day simple moving average is $3.81 and its 200 day simple moving average is $2.94.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, hitting the consensus estimate of ($0.19). Iovance Biotherapeutics had a negative return on equity of 54.54% and a negative net margin of 148.41%.The business had revenue of $71.43 million during the quarter, compared to the consensus estimate of $77.84 million. During the same period in the prior year, the company posted ($0.36) EPS. The business’s quarterly revenue was up 44.9% on a year-over-year basis. As a group, equities research analysts forecast that Iovance Biotherapeutics will post -0.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Invenomic Capital Management LP grew its stake in shares of Iovance Biotherapeutics by 27.1% in the 3rd quarter. Invenomic Capital Management LP now owns 10,541,608 shares of the biotechnology company’s stock valued at $22,875,000 after buying an additional 2,246,945 shares during the period. Mirador Capital Partners LP raised its position in shares of Iovance Biotherapeutics by 100.9% during the 4th quarter. Mirador Capital Partners LP now owns 1,034,544 shares of the biotechnology company’s stock valued at $2,824,000 after buying an additional 519,519 shares during the period. Aberdeen Group plc raised its position in shares of Iovance Biotherapeutics by 25.1% during the 4th quarter. Aberdeen Group plc now owns 759,522 shares of the biotechnology company’s stock valued at $2,073,000 after buying an additional 152,312 shares during the period. Rhenman & Partners Asset Management AB lifted its holdings in Iovance Biotherapeutics by 69.5% in the third quarter. Rhenman & Partners Asset Management AB now owns 1,097,827 shares of the biotechnology company’s stock valued at $2,382,000 after acquiring an additional 450,000 shares during the last quarter. Finally, Rafferty Asset Management LLC grew its position in Iovance Biotherapeutics by 65.1% in the third quarter. Rafferty Asset Management LLC now owns 482,975 shares of the biotechnology company’s stock worth $1,048,000 after acquiring an additional 190,522 shares during the period. Hedge funds and other institutional investors own 77.03% of the company’s stock.

More Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported 1Q26 total revenue of ~$71M, a ~45% year‑over‑year increase, issued 2Q26 revenue guidance of $86M–$88M and FY26 revenue guidance of $350M–$370M, and highlighted a 40% confirmed objective response rate in metastatic serous endometrial cancer — all supportive of commercial and clinical momentum. GlobeNewswire Release
• Positive Sentiment: Company outlined FY26 revenue range of $350M–$370M and Q2 revenue $86M–$88M in filings/updates, providing forward visibility that could support valuation if execution matches guidance. Seeking Alpha: Guidance Outline
• Neutral Sentiment: Chardan Capital cut its price target from $16 to $14 but maintained a “buy” rating — a vote of continued analyst confidence but with reduced upside expectations that tempers enthusiasm. Benzinga Note
• Neutral Sentiment: Iovance’s Q1 EPS of ($0.19) matched consensus and improved versus last year’s ($0.36), showing progress on profitability metrics even as the company remains unprofitable on a GAAP basis. MarketBeat: Earnings Summary
• Negative Sentiment: Revenue of $71.43M missed analyst estimates (~$77.8M), a key reason for the stock pullback as investors focus on near‑term commercial performance versus expectations. Zacks: Revenue Miss
• Negative Sentiment: Market commentary and headlines noted the quarter as a “miss” and the stock has reacted downward; investors may be trimming positions until upcoming quarterly cadence confirms guidance execution. Seeking Alpha: Market Reaction
• Neutral Sentiment: For detail, the Q1 2026 earnings call transcript is available for investors wanting management color on commercial trends, pharmacy dynamics, and clinical updates. Earnings Call Transcript

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.